Table 1.
Characteristics of the Study Group
| n (%) | |
|---|---|
| Total pairs | 113 (100%) |
| Age | |
| <60 years | 76 (67.3) |
| >60 years | 37 (32.7) |
| Median | 55 years |
| FIGO stage primary | |
| FIGO I | 2 (1.8) |
| FIGO II | 6 (5.3) |
| FIGO III | 93 (82.3) |
| FIGO IV | 12 (10.6) |
| Recurrence used for IHC | |
| 1st | 98 (86.7) |
| 2nd | 6 (5.3) |
| 3rd | 7 (6.2) |
| Other | 2 (1.8) |
| Postoperative residual tumor | |
| None | 79 (69.9) |
| Any | 34 (30.1) |
| First-line chemotherapy | |
| Taxol/carboplatin | 88 (77.9) |
| Other platinum-based | 19 (16.8) |
| Other | 6 (5.3) |
| Platinum sensitivity status after 1st-line treatment | |
| Sensitive | 89 (78.8) |
| Resistant | 16 (14.2) |
| Missing | 8 |
| Platinum sensitivity status after 2nd-line treatmenta | |
| Sensitive | 58 (84.1) |
| Resistant | 11 (15.9) |
| Missing | 29 |
| BRCA germline status | |
| wt | 12 (57.1) |
| BRCA1 mt | 7 (33.3) |
| BRCA2 mt | 2 (9.5) |
| Missing | 94 |
| BRCA tumor status (includes germline and somatic mt)b | |
| wt | 31 (58.5) |
| BRCA1 mt | 16 (30.2) |
| BRCA2 mt | 6 (11.3) |
| Missing | 60 |
a
First recurrence only
b
BRCA status in tumor tissue was identical in all pairs of primary and recurrent tumors.